Live Breaking News & Updates on Reclinical Research

Stay updated with breaking news from Reclinical research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

New treatment targeting aging cells could offer lasting relief for diabetic macular edema

Targeting senescent cells in the retina with a BCL-xL inhibitor shows promise as a durable treatment for diabetic macular edema, potentially offering long-term visual function improvements. ....

Anukool Manoton , Nature Medicine , Diabetic Macular Edema , Macular Edema , Blood Vessels , Diabetic Retinopathy , Growth Factor , Vision Loss ,

Tetra Pharm Technologies advances CB1 antagonist | TPT0701 | for appetite suppression into preclinical testing

- The Danish bioPharmaceutical company, Tetra Pharm Technologies, proudly announces a significant milestone in the realm of appetite suppression research . ....

Tetra Pharm Technologies , Intellectual Property ,

AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial

AMG 133, an engineered bispecific molecule, demonstrated significant weight loss with a favorable safety profile in a phase 1 clinical trial, offering a promising new treatment option for obesity. ....

Nature Metabolism , Weight Loss , Clinical Trial , Glp 1 , Public Health ,

Spexis announces closing of sale of preclinical antibiotics program to Basilea - adhoc - Börsennachrichten

Spexis AG Key word Miscellaneous Spexis announces closing of sale of preclinical antibiotics program to Basilea 08Feb2024 0715 CETCEST Release of an ad hoc announcement pursuant to Art 53 LR The issu ....

Switzerland General , Stephan Feldhaus , Basilea Pharmaceutica , Canton Basel Landschaft , Stephen Jasper , Germany Federal Ministry Of Education , Us Department Of Health , Development Authority , World Health Organization , Gilmartin Group , Human Services , Biomedical Advanced Research , Administration For Strategic Preparedness , District Court , Western District Court , Science Advances , Strategic Preparedness , Federal Ministry ,

Hope for relapsed myeloma: Preclinical and clinical evidence for ruxolitinib's efficacy

A new research perspective was published in Oncotarget's Volume 15 on February 5, 2024, entitled, "Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma." ....

Jamesr Berenson , Elizabeth Tadevosyan , Berenson Cancer Center , Institute For Myeloma , Bone Cancer Research , Janus Kinase , Ashley Del Dosso , Kinase Inhibitor , Multiple Myeloma ,